PRA Adds Large Molecule Capabilities to U.S. Laboratory

RALEIGH, N.C. and LENEXA, Kan., May 13, 2014 /PRNewswire/ -- PRA, a leading clinical research organization, today announced that in addition to offering full-service bioanalytical capabilities in its Assen, The Netherlands, laboratory, it will add immunochemistry services in its Lenexa , Kan. , laboratory. PRA is now the only company in the world with full-service bioanalytical capabilities near its clinics to support rapid results from Phase I clinical studies in both the U.S. and Europe, facilitating complex and adaptive study design.

"By expanding our services to large molecule bioanalysis, we can now support all types of clinical trials," said Chad Briscoe, Ph.D, PRA executive director, Science & Innovations, Bioanalytical Laboratories. "It is an important addition to our services because the contribution of large molecules in drug research and the development of biosimilars have increased rapidly over the past few years."  

PRA's Early Development Services group is committed to the highest standards of clinical excellence and scientific expertise. With more than 1,000 staff, 500 beds, eight clinics and two laboratories, it is the most comprehensive early development organization in the world. From its state-of-the-art facilities, the group provides the pharmaceutical and biotech industries with the unique scientific environment required for complex compound development and testing in both healthy volunteers and patients. In addition, PRA's harmonized laboratory facilities in The Netherlands and the U.S. are situated close to the clinical facilities and are configured to fully support all clinical study requirements.

About PRA
One of the world's largest CROs, PRA is transforming clinical trials through our people, innovation and operational transparency. Our 10,000+ employees operate in more than 80 countries, delivering a broad spectrum of full-service and Embedded clinical trial solutions that meet the demands of a diverse marketplace.

Over the last 30+ years, PRA has established a reputation for specialized expertise and success in a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. Our forward-thinking approach to clinical research innovation, customized recruitment strategies and technological advances continues to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email [email protected].

SOURCE PRA